A study to compare effectiveness and tolerability of Bimatoprost and Timolol eye drops in Open Angle Glaucoma.
- Conditions
- Health Condition 1: H401- Open-angle glaucoma
- Registration Number
- CTRI/2022/07/044079
- Lead Sponsor
- Dr Sreyanwita Mukherjee
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
•Age: 18 to 60 years of age of either sex.
Patients with newly diagnosed, drug naive, primary open angle glaucoma patients of either sex attending the Department of Ophthalmology OPD at College of Medicine & Sagore Dutta Hospital, Kamarhati, Kolkata.
•Patient who will give the written informed consent form voluntarily and are available during the entire study duration.
•Pregnant or lactating women.
• Patients who are suffering from other congenital glaucoma secondary to other ophthalmic conditions.
• Patient who has undergone any kind of medical and surgical treatment in the past.
•Patient who has undergone corrective refractive surgery.
•Patients with uncontrolled Hypertension, Diabetes mellitus.
•Patients receiving chemotherapy for Malignancy.
•Patients having infection in one or both eyes within the last three months.
•Patients having ocular injury within last three months.
• Patients suffering from major systemic illness or features of severe systemic infection are excluded from the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the efficacy of the two drugs, Bimatoprost and Timolol in terms of reduction of intraocular pressure for the treatment of Primary Open Angle Glaucoma from baseline visit, visit at fourth weeks and upto eight weeks.Timepoint: At baseline visit, visit at fourth weeks and eight weeks.
- Secondary Outcome Measures
Name Time Method To compare the safety of the two drugs, Bimatoprost and Timolol in terms of adverse effect for the treatment of Primary Open Angle Glaucoma from base line visit, visit at fourth weeks, upto visit at eight weeks.Timepoint: At baseline visit, visit at fourth weeks and eight weeks.